Liu X(1)(2), Wang H(1)(2), Wu X(1)(2), Hong X(1)(2), Luo Z(3)(4)
(1)Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.(2)Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.(3)Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China.(4)Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Publication
Invest New Drugs
Summary
To evaluate the efficacy and safety of doxorubicin (ADM) combined with thalidomide (THA) as a first-line treatment for patients with refractory aggressive fibromatosis (AF). No patient had a complete response, but five patients had partial responses, resulting in a RR of 33%. Eight patients (53%) had stable disease and two patients (13%) had progressive disease, and the disease control rate was 87%. ADM plus THA was well-tolerated and effective as a first-line treatment for patients with refractory AF. However, patients with hypoalbuminemia at baseline had inferior clinical outcomes, and further studies are needed to investigate this issue.
Stay Up to Date as We Uncover More About Desmoid Tumors
